

Phase I trial of targeted alpha-particle therapy with actinium-225 (225Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with ...

JG Jurcic, MY Levy, JH Park, F Ravandi, AE Perl, JM Pagel, BD Smith, EH Estey...

Blood, 2016 • Elsevier

Abstract

[SHOW MORE](#) ▼

☆ Save  Cite Cited by 59 Related articles All 3 versions

**Patent Owner Exhibit 2171
IPR2025-01582**